Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Geron Corp. -- Ignore unavailable to you. Want to Upgrade?

To: FJB who wrote (3297)	7/8/2011 9:19:49 PM
From: Savant	Respond to of 3576

RT..Stem-cell stocks rise on artificial-trachea report By Val Brickates Kennedy, MarketWatch Last Update: 7/8/2011 02:56:49 PM BOSTON (MarketWatch) -- Shares of several stem-cell research companies jumped Friday following news that Swedish doctors were able to replace the trachea of a patient suffering from advanced cancer with one grown from the man's stem cells. StemCells Inc. was the sharpest gainer, with shares shooting up 20% to $6.15, followed by Geron Corp. (GERN), up 9%, and Australia's Mesoblast Ltd. (MBLTY), up 4%. Also gaining at least 2% were shares of Pluristem Therapeutics (PSTI), Athersys Inc. (ATHX) , Osiris Therapeutics (OSIR) , Advanced Cell Technology (ACTC) , and Cytori Therapeutics.(CYTX). Early Friday, doctors at Sweden's Karolinska University Hospital announced that they had essentially saved the life of a man whose trachea, or windpipe, had become almost completely blocked by a cancerous tumor. They by replacing it with one grown using stem cells taken from his bone marrow. Read more on artificial trachea... online.wsj.com